| Pharmaceutical Information |
| Drug Name |
Golimumab |
| Drug ID |
BADD_D01035 |
| Description |
Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications. In the U.S. and Canada, golimumab is marketed under the brand name Simponi®. The FDA label includes a black box warning of serious infections and malignancy. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed. |
| Indications and Usage |
Used in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA)[L16626], (ii) in patients 2 years old and above with active psoriatic arthritis (PsA)[L16626], (iii) as a single agent in patients with active ankylosing spondylitis (AS) or in combination with methotrexate[L16631], and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications.[L16631] It is also indicated (v) for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older.[L16626]
|
| Marketing Status |
approved |
| ATC Code |
L04AB06 |
| DrugBank ID |
DB06674
|
| KEGG ID |
D04358
|
| MeSH ID |
C529000
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D09FSG
|
| NDC Product Code |
57894-070; 65267-899; 57894-071; 57894-350 |
| UNII |
91X1KLU43E
|
| Synonyms |
golimumab | CNTO-148 | CNTO 148 | Simponi |
|
| Chemical Information |
| Molecular Formula |
Not Available |
| CAS Registry Number |
476181-74-5 |
| SMILES |
Not Available |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
|
